Crispr Therapeutics (NASDAQ:CRSP) was upgraded by equities research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, November 12th, Marketbeat Ratings reports. The brokerage currently has a $65.00 price objective on the stock. Oppenheimer’s price target would suggest a potential downside of 9.28% from the company’s previous close. Oppenheimer also issued estimates for Crispr Therapeutics’ Q1 2020 earnings at ($0.87) EPS, Q2 2020 earnings at ($0.95) EPS, Q3 2020 earnings at ($1.29) EPS, Q4 2020 earnings at ($1.38) EPS, FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.
A number of other analysts have also weighed in on CRSP. Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a research report on Thursday, August 1st. They issued a “buy” rating and a $64.00 target price on the stock. Canaccord Genuity started coverage on shares of Crispr Therapeutics in a report on Friday, July 26th. They set a “buy” rating and a $72.00 price target on the stock. Barclays lifted their price target on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Finally, William Blair reiterated a “hold” rating on shares of Crispr Therapeutics in a report on Tuesday, July 30th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $69.54.
NASDAQ:CRSP traded up $3.54 during mid-day trading on Tuesday, reaching $71.65. The stock had a trading volume of 1,013,423 shares, compared to its average volume of 1,446,979. The stock has a 50-day simple moving average of $49.98 and a two-hundred day simple moving average of $46.23. The stock has a market capitalization of $3.76 billion, a PE ratio of -20.83 and a beta of 3.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Equities analysts expect that Crispr Therapeutics will post 0.65 EPS for the current year.
In other news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. boosted its stake in Crispr Therapeutics by 324.3% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. ARK Investment Management LLC lifted its stake in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after buying an additional 701,332 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at approximately $21,167,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares in the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Stop Order Uses For Individual Investors
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.